Enhancement of AP-1 DNA-binding activity during amphetamine- and phencyclidine-mediated behaviour in rats

Neuropharmacology

Volumn 50, Issue 8, 2006, Pages 924-933

  Milanovic, Desanka ^a   Pesic, Vesna ^a   Rakic, Ljubisav ^b   Kanazir, Selma ^a   Ruzdijic, Sabera ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SERBIAN ACADEMY OF SCIENCES AND ARTS   (Serbia)

Author keywords

Amphetamine; AP 1 binding activity; c Fos; c Jun; Locomotor activity; Phencyclidine

Indexed keywords

AMPHETAMINE; DNA; PHENCYCLIDINE; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

AMINO ACID SEQUENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; GEL MOBILITY SHIFT ASSAY; HIPPOCAMPUS; INHIBITION KINETICS; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; STATISTICAL SIGNIFICANCE;

EID: 33646931738     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.01.011     Document Type: Article

References (41)

1. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. The Journal of Neuroscience 18 (1998) 5545-5554
2. Balla A., Sershen H., Serra M., Koneru R., and Javitt D.C. Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release. Neuropsychopharmacology 28 (2003) 34-44
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1976) 248-254
4. Carlsson A., Hansson L.O., Waters N., and Carlsson M.L. A glutamatergic deficiency model of schizophrenia. British Journal of Psychiatry 174 (1999) 2-6
5. Chapman M.A., and Zahm D.S. Altered Fos-like immunoreactivity in terminal regions of the mesotelencephalic dopamine system is associated with reappearance of tyrosine hydroxylase immunoreactivity at the sites of focal 6-hydroxydopamine lesions in the nucleus accumbens. Brain Research 736 (1996) 270-279
6. Gleason S.D., and Shannon H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology 129 (1997) 79-84
7. Graybiel A.N., Mortalla R., and Robertson H.A. Amphetamine and cocaine induced drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proceedings of the National Academy of Sciences of the USA 87 (1990) 6912-6916
8. Herdegen T., and Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Research Reviews 28 (1998) 370-490
9. Hollen K.M., Nakabeppu Y., and Davies S.W. Changes in expression of delta FosB and the Fos family proteins following NMDA receptor activation in the rat striatum. Brain Research Molecular Brain Research 47 (1997) 31-43
10. Huang K.X., and Walters J.R. Dopaminergic regulation of AP-1 transcription factor DNA binding activity in rat striatum. Neuroscience 75 3 (1996) 757-775
11. Hughes P., and Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacological Reviews 47 (1995) 133-178
12. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., and Bloch B. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 65 (1995) 1041-1050
13. Jentsch J.D., Tran A., Taylor J.R., and Roth R.H. Prefrontal cortical involvement in phencyclidine-induced activation of the mesolimbic dopamine system: behavioural and neurochemical evidence. Psychopharmacology 138 (1998) 89-95
14. Kallunki T., Deng T., Hibi M., and Karin M. c-Jun can recruit JNK to phosphorylation dimerization partners via specific docking interactions. Cell 87 (1996) 929-939
15. Karin M., Liu Z., and Zandi E. AP-1 function and regulation. Current Opinion in Cell Biology 9 (1997) 240-246
16. Kitaichi K., Noda Y., Hasegawa T., Furukawa H., and Nebeshima T. In vivo functional interaction between phencyclidine binding sites and sigma receptors to produce head-weaving behavior in rats. European Journal of Pharmacology 318 (1996) 205-211
17. Mathe J.M., Nomikos G.G., Blakeman K.H., and Svensson T.H. Differential actions of dizocilpine (MK-801) on the mezolimbic and mezocortical dopamine systems: role of neuronal activity. Neuropharmacology 38 (1999) 121-128
18. Milanovic D., Milosevic J., Kanazir S., Rakic L., and Ruzdijic S. Effect of amphetamine and phencyclidine on DNA-binding activities of serum response and dyad symetry elements. Neurochemistry International 42 (2003) 409-417
19. Morgan J.I., and Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annual Review of Neuroscience 14 (1991) 421-451
20. Nye H.E., Hope B.T., Kelz M.B., Iadarola M., and Nestler E.J. Pharmacological studies of the regulation of chronic fos-related antigen induction by cocaine in the striatum and nucleus accumbens. The Journal of Pharmacology and Experimental Therapeutics 275 (1995) 1671-1680
21. Ogita K., and Yoneda Y. Selective potentiation of DNA binding activities of both activator protein 1 and cyclic AMP response element binding protein through in vivo activation of N-methyl-d-aspartate receptor complex in mouse brain. Journal of Neurochemistry 63 (1994) 525-534
22. Pesic V., Janac B., Milanovic D., Tomic M., Veskov R., and Rakic L. Motor effects of amphetamine in rats pretreated with either dizocilpine or phencyclidine. Behavioral Brain Research 147 (2003) 211-215
23. Platenik J., Kuramoto N., and Yoneda Y. Molecular mechanisms associated with long-term consolidation of the NMDA signals. Life Sciences 67 (2000) 335-364
24. Raiteri M., Cerrito F., Cervoni A.M., and Levi G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. The Journal of Pharmacology and Experimental Therapeutics 208 (1979) 195-202
25. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive sensitisation theory of addiction. Brain Research Reviews 28 (1993) 274-291
26. Sarter M., and Bruno P.J. Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends in Neurosciences 22 (1999) 67-74
27. Seiden L.S., Sabol K.E., and Ricaurte G.A. Amphetamine: effects on catecholamine systems and behaviour. Annual Reviews of Pharmacology and Toxicology 32 (1993) 369-677
28. Self D.W. Regulation of drug-taking and -seeking behaviours by neuroadaptations in the mesolimbic dopamine system. Neuropharmacology 47 (2004) 242-255
29. Sharp T., Zetterstrom T., Ljungberg T., and Ungerstedt U. A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Research 401 (1987) 322-330
30. Sharp F.R., Hisanaga K., and Sagar S.M. NMDA receptor blockade prevents translation, but not transcription, of the c-fos gene following stimulation with multiple extracellular signals in cultured cortical neurons: implications for plasticity and molecular memory. NIDA Research Monograph 125 (1993) 172-180
31. Simpson J.N., Wang J.Q., and McGinty J.F. Repeated amphetamine administration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and Fos-related antigen immunoreactivity in rat striatum. Neuroscience 69 (1995) 441-457
32. Sonnenberg J.L., Mitchelmore C., Macgregor-Leon P.F., Hempstead J., Morgan J.I., and Curran T. Glutamate receptor agonists increase the expression of Fos, Fra and AP-1 DNA binding activity in the mammalian brain. Journal of Neuroscience Research 24 (1989) 72-80
33. Steinpreis R.E. The behavioural and neurochemical effects of phencyclidine in humans and animals: some implications for modelling psychosis. Behavioural Brain Research 74 (1996) 45-55
34. Steinpreis R.E., and Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: a microdialysis and behavioral study. Brain Research 612 (1992) 263-270
35. Steketee J.D. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain Research Brain Research Reviews 41 (2003) 203-228
36. Sturgeon R.D., Fessler R.G., and Meltzer H.Y. Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behavior and ataxia in rats. European Journal of Pharmacology 59 (1979) 169-179
37. Szekely A.M., Costa E., and Grayson D.R. Transcriptional program coordination by N-methyl-d-aspartate-sensitive glutamate receptor stimulation in primary cultures of cerebellar neurons. Molecular Pharmacology 38 (1990) 624-633
38. Turgeon S.M., and Case T.C. The effects of phencyclidine pre-treatment on amphetamine-induced behavior and c-Fos expression in the rat. Brain Research 888 (2001) 302-305
39. Turgeon S.M., Pollack A.E., and Fink J.S. Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. Brain Research 749 (1997) 120-126
40. Vasilev V., Veskov R., Janac B., Rakic L., and Stojiljkovic M. Age-related differences in MK-801- and amphetamine-induced locomotor and stereotypic activities of rats. Neurobiology of Aging 24 (2003) 715-723
41. Vukosavic, S., Ruzdijic, S., Veskov, R., Rakic, L., Kanazir, S.,, 2001. Differential effects of amphetamine and phencyclidine on the expression of growth-associated protein.